{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T13:45:57Z","timestamp":1749735957200},"reference-count":25,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>A population pharmacokinetic model of telavancin, a lipoglycopeptide antibiotic, was developed and used to identify sources of interindividual variability. Data were obtained from healthy subjects (seven phase 1 studies), patients with complicated skin and skin structure infections (cSSSI; two phase 2 and two phase 3 studies), and patients with hospital-acquired pneumonia (HAP; two phase 3 studies). A two-compartment open model with zero-order input best fit the telavancin data from healthy individuals and patients with cSSSI or HAP. Telavancin clearance was highly correlated with renal function and, to a lesser extent, with body weight. Other covariates were related to at least one parameter in cSSSI (gender, bacterial eradication, and surgery) or HAP (age of \u226575 years) but did not markedly affect exposure. These analyses support current dosing recommendations for telavancin based on patient weight and renal function.<\/jats:p>","DOI":"10.1128\/aac.05915-11","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T05:13:08Z","timestamp":1326863588000},"page":"2067-2073","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections"],"prefix":"10.1128","volume":"56","author":[{"given":"Emil","family":"Samara","sequence":"first","affiliation":[{"name":"PharmaPolaris International, Inc., Danville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng-Pyng","family":"Shaw","sequence":"additional","affiliation":[{"name":"Theravance, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Barriere","sequence":"additional","affiliation":[{"name":"Theravance, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shekman L.","family":"Wong","sequence":"additional","affiliation":[{"name":"Theravance, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Worboys","sequence":"additional","affiliation":[{"name":"Theravance, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Vibativ package insert","author":"Astellas Pharma US, Inc","year":"2009","unstructured":"Astellas Pharma US, Inc. 2009. Vibativ package insert. Astellas Pharma US, Inc, Deerfield, IL."},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/0091270004266620","article-title":"Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects","volume":"44","author":"Barriere S","year":"2004","unstructured":"BarriereS. 2004. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. 44:689\u2013695.","journal-title":"J. Clin. Pharmacol"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1152\/jappl.1995.79.1.94","article-title":"Relative expansion of extracellular water in obese vs. normal children","volume":"79","author":"Battistini N","year":"1995","unstructured":"BattistiniN. 1995. Relative expansion of extracellular water in obese vs. normal children. J. Appl. Physiol. 79:94\u201396.","journal-title":"J. Appl. Physiol"},{"key":"e_1_3_3_5_2","volume-title":"NONMEM user's guides, parts I to VIII","author":"Beal SL","year":"1988","unstructured":"BealSL SheinerLB. 1988\u20131998. NONMEM user's guides, parts I to VIII. NONMEM Project Group, University of California at San Francisco, San Francisco, CA."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_7_2","volume-title":"14th Eur. Congr. Clin. Microbiol. Infect. Dis","author":"Duchin K","year":"2004","unstructured":"DuchinK. 2004. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction, abstr 1028. 14th Eur. Congr. Clin. Microbiol. Infect. Dis. Prague, Czech Republic, 1 to 4 May 2004."},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1592\/phco.30.1.35","article-title":"Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin","volume":"30","author":"Goldberg MR","year":"2010","unstructured":"GoldbergMR WongSL ShawJP KittMM BarriereSL. 2010. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 30:35\u201342.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.30.8.806","article-title":"Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women","volume":"30","author":"Goldberg MR","year":"2010","unstructured":"GoldbergMR WongSL ShawJP KittMM BarriereSL. 2010. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 30:806\u2013811.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-07"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-07"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7164\/antibiotics.57.326","article-title":"Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)","volume":"57","author":"Leadbetter MR","year":"2004","unstructured":"LeadbetterMR. 2004. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo) 57:326\u2013336.","journal-title":"J. Antibiot. (Tokyo)"},{"key":"e_1_3_3_15_2","volume-title":"20th Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Lodise T","year":"2010","unstructured":"LodiseT. 2010. Mouse thigh MRSA infection model data and mathematical modelling to determine telavancin dosing for complicated skin and skin structure infection trials, abstr P1602. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria, 10 to 13 April 2010."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00383-11"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.862-867.2006"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/429914"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.788-790.2006"},{"key":"e_1_3_3_24_2","first-page":"E199","article-title":"Relative expansion of extracellular fluid in obese vs. nonobese women","volume":"261","author":"Waki M","year":"1991","unstructured":"WakiM. 1991. Relative expansion of extracellular fluid in obese vs. nonobese women. Am. J. Physiol. 261:E199\u2013E203.","journal-title":"Am. J. Physiol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkn273","article-title":"Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects","volume":"62","author":"Wong SL","year":"2008","unstructured":"WongSL BarriereSL KittMM GoldbergMR. 2008. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62:780\u2013783.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1592\/phco.30.2.136","article-title":"Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects","volume":"30","author":"Wong SL","year":"2010","unstructured":"WongSL GoldbergMR BallowCH KittMM BarriereSL. 2010. Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy 30:136\u2013143.","journal-title":"Pharmacotherapy"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05915-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05915-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:16:04Z","timestamp":1645481764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05915-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1128\/AAC.05915-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05915-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"2011-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}